ArticleFrontiers in endocrinology2022
Efficacy of radiofrequency ablation for metastatic papillary thyroid cancer with and without initial biochemical complete status.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Radiofrequency Ablation for Recurrent Thyroid Cancers: 2025 Korean Society of Thyroid Radiology Guideline.Korean journal of radiology · 2025Guideline
- Long-Term Outcomes of Radiofrequency Ablation for Benign Thyroid Nodules of Different Sizes: Implications of Regrowth and New Growth.The Kaohsiung journal of medical sciences · 2026Article
- Laryngectomy-Sparing Radio Frequency Ablation for Laryngeal Metastasis in Recurrent Papillary Thyroid Carcinoma: A Case Report.Case reports in endocrinology · 2026Article
- Radiofrequency Ablation for Recurrent Papillary Thyroid Carcinoma at the Central Compartment Node: A Case Report.The Indian journal of radiology & imaging · 2025Article
- Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece.Biomedicines · 2025Article
- Radiofrequency ablation for difficult thyroid nodule resulting complete resolution after following 6 months: a case report.Journal of visualized surgery · 2025Article
- Article
- Ultrasound-guided radiofrequency ablation for the treatment of papillary thyroid carcinoma: a review of the current state and future perspectives.Ultrasonography (Seoul, Korea) · 2024Article
- 2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation.Ultrasonography (Seoul, Korea) · 2023Article
- Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines · 2023Review
- A novel case of EUS-guided targeted radiofrequency ablation of metastatic duodenal renal cell carcinoma.Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The application of radiofrequency ablation (RFA) for recurrent thyroid cancer has been demonstrated to effectively manage lesions at critical locations, such as abutting the trachea, with limited complications. Comprehensive investigation of both biochemical (B) and structural (S) change after RFA remains limited. We herein present the first single-center experience of RFA for the treatment of locoregional recurrent thyroid cancer in Taiwan. Design: 23 patients were enrolled, and the treatment responses after RFA were divided into four groups ( Results: In patients with pre-RFA structural and biochemical incomplete ( Conclusions: This retrospective study reveals that RFA can achieve both structural and biochemical improvements for locoregionally recurrent thyroid cancer, with a low complication rate. Nearly half of the patients achieved an excellent response after RFA, while a favorable treatment response can be achieved despite the lesion abutting the trachea, with a mean VRR of 84.74%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.